Komori
Fuso Pharmaceutical Industries (4538) · FactUpdated full-year cash balance and cash flow

Increase in Cash and Cash Equivalents and Financing Cash Flow from Borrowings

First written in FY2018-Q2. . Latest entry: FY2026.

29entries
10years
0from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseOtherFY2018-Q2 – FY20262017: 12018: 320182019: 420192020: 420202021: 420212022: 420222023: 320232024: 320242025: 220252026: 12026
Same theme, other companies
Cash Flow Changes from the Use of Funds in Operating and Investing Activities and FinancingA theme 123 companies write about · 55 as a headwind · 29 as a tailwind

80 other companies' latest entry also says "Other".

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 123 companies compared. The sentences above are computed from all 123.
Full recordFilings, disclosures and news, newest first
  1. FY2026Updated full-year cash balance and cash flowAnnual report

    「Cash and cash equivalents at the end of the fiscal year decreased by ¥1,418 million from the end of the previous fiscal year to ¥4,846 million.」

    Cash and cash equivalents at fiscal year-end were ¥4,846 million, down ¥1,418 million from the end of the previous fiscal year. Operating activities used ¥6,224 million due to the impact of litigation-related advances, while financing activities generated ¥6,321 million due to an increase in short-term borrowings.
  2. FY2026-H1Update to interim cash balance and cash flowAnnual report

    「Cash and cash equivalents at the end of the interim accounting period decreased by ¥1,625 million from the end of the previous fiscal year to ¥4,638 million. Operating activities used ¥5,367 million, despite the recording of interim net income before income taxes and the decrease in trade receivables, due to the payment of ¥8,744 million in advance payments related to the litigation described above. Financing activities generated ¥4,544 million, despite repayments of long-term borrowings and dividend payments, due to an increase in short-term borrowings related to the litigation described above.」

    Cash and cash equivalents decreased by ¥1,625 million to ¥4,638 million. Operating cash flow was an outflow of ¥5,367 million due to the payment of litigation-related advances, while financing cash flow was an inflow of ¥4,544 million due to an increase in short-term borrowings.
  3. FY2025Updated full-year cash balance and cash flowAnnual report

    「Cash and cash equivalents at the end of the fiscal year increased by ¥1,144 million from the end of the previous fiscal year to ¥6,264 million. Operating activities used ¥3,305 million, despite the recording of depreciation and amortization and provisions for litigation-related losses, due to the recording of a loss before income taxes and the increase in trade receivables and decrease in trade payables. Financing activities generated ¥7,618 million, despite the decrease in long-term borrowings and dividend payments, due to an increase in short-term borrowings.」

    Cash and cash equivalents increased by ¥1,144 million to ¥6,264 million. Operating cash flow was an outflow of ¥3,305 million, while financing cash flow was an inflow of ¥7,618 million due to an increase in short-term borrowings.
  4. FY2025-H1Update to interim cash balance and cash flowAnnual report

    「Cash and cash equivalents at the end of the interim accounting period decreased by ¥502 million from the end of the previous fiscal year to ¥4,617 million.」

    Cash and cash equivalents at the end of the interim period were ¥4,617 million, down ¥502 million from the end of the previous fiscal year. Operating activities generated ¥769 million, investing activities used ¥1,749 million, and financing activities generated ¥477 million.
  5. FY2024Updated full-year cash balance and cash flowAnnual report

    「At the end of the fiscal year, cash and cash equivalents decreased by ¥2,894 million from the end of the previous fiscal year to ¥5,120 million.」

    Cash and cash equivalents at fiscal year-end were ¥5,120 million. Operating activities generated ¥627 million, investing activities used ¥3,536 million, and financing activities generated ¥14 million.
  6. FY2024-Q3Third-quarter-end cash balance updatedAnnual report

    「Cash and deposits 8,014 6,678」

    Cash and deposits decreased from ¥8,014 million at the end of the previous fiscal year to ¥6,678 million at the end of the third quarter.
  7. FY2024-Q2Updated first-half cash balance and cash flowAnnual report

    「At the end of the cumulative second-quarter period, cash and cash equivalents decreased by ¥492 million from the end of the previous fiscal year to ¥7,522 million.」

    Cash and cash equivalents decreased by ¥492 million from the end of the previous fiscal year to ¥7,522 million. Cash flow from operating activities used ¥341 million, investing activities used ¥1,422 million, and financing activities provided ¥1,272 million.
  8. FY2023Updated full-year cash balance and cash flowAnnual report

    「At the end of the fiscal year, cash and cash equivalents increased by ¥667 million from the end of the previous fiscal year to ¥8,014 million.」

    At the end of FY2023, cash and cash equivalents were ¥8,014 million, up ¥667 million from the end of the previous fiscal year. Operating activities provided ¥2,853 million, investing activities used ¥1,373 million, and financing activities used ¥813 million.
  9. FY2023-Q3Third-quarter-end cash balance updatedAnnual report

    「Cash and deposits 7,347 8,148」

    Cash and deposits were ¥8,148 million at the end of the third quarter, up from ¥7,347 million at the end of the previous fiscal year.
  10. FY2023-Q2Updated second-quarter cash balance and cash flowAnnual report

    「At the end of the cumulative second-quarter period, cash and cash equivalents increased by ¥1,352 million from the end of the previous fiscal year to ¥8,699 million.」

    Cash and cash equivalents increased by ¥1,352 million from the end of the previous fiscal year to ¥8,699 million. Operating activities provided ¥1,305 million, investing activities used ¥386 million, and financing activities provided ¥434 million.
  11. FY2023-Q1First-quarter-end cash balance updatedAnnual report

    「Cash and deposits 7,347 9,385」

    Cash and deposits increased from ¥7,347 million at the end of the previous fiscal year to ¥9,385 million at the end of the first quarter, an increase of ¥2,038 million. No cash flow statement was prepared for the cumulative first-quarter period.
  12. FY2022Updated full-year cash balance and cash flowAnnual report

    「At the end of the fiscal year, cash and cash equivalents increased by ¥273 million from the end of the previous fiscal year to ¥7,347 million.」

    At the end of FY2022, cash and cash equivalents were ¥7,347 million, up ¥273 million from the end of the previous fiscal year. Operating activities provided ¥3,498 million, investing activities used ¥1,553 million, and financing activities used ¥1,671 million.
  13. FY2022-Q3Third-quarter-end cash balance updatedAnnual report

    「Cash and deposits 7,074 8,238」

    Cash and deposits increased from ¥7,074 million at the end of the previous fiscal year to ¥8,238 million at the end of the third quarter. No cash flow statement was prepared for the cumulative third-quarter period.
  14. FY2022-Q2Updated second-quarter cash balance and cash flowAnnual report

    「At the end of the cumulative second-quarter period, cash and cash equivalents increased by ¥1,603 million from the end of the previous fiscal year to ¥8,677 million.」

    Cash and cash equivalents increased by ¥1,603 million from the end of the previous fiscal year to ¥8,677 million. Cash flow from operating activities was ¥1,945 million, investing activities used ¥610 million, and financing activities provided ¥268 million.
  15. FY2022-Q1First-quarter-end cash balance updatedAnnual report

    「Cash and deposits 7,074 7,459」

    Cash and deposits increased from ¥7,074 million at the end of March 2021 to ¥7,459 million at the end of June 2021, an increase of ¥385 million. No cash flow statement was prepared for the cumulative first-quarter period.
  16. FY2021Updated full-year cash balance and cash flowAnnual report

    「At the end of the fiscal year, cash and cash equivalents decreased by ¥194 million from the end of the previous fiscal year to ¥7,074 million.」

    At the end of FY2021, cash and cash equivalents were ¥7,074 million, down ¥194 million from the end of the previous fiscal year. Cash flow from operating activities was ¥3,230 million, investing activities used ¥978 million, and financing activities used ¥2,446 million.
  17. FY2021-Q3Third-quarter-end cash balance updatedAnnual report

    「Cash and deposits 7,268 8,311」

    Cash and deposits were ¥8,311 million at the end of the third quarter, up ¥1,043 million from ¥7,268 million at the end of the previous fiscal year. No cash flow statement was prepared for the cumulative third-quarter period.
  18. FY2021-Q2Updated second-quarter cash balance and cash flowAnnual report

    「At the end of the cumulative second-quarter period, cash and cash equivalents increased by ¥833 million from the end of the previous fiscal year to ¥8,101 million.」

    Cash and cash equivalents increased by ¥833 million from the end of the previous fiscal year to ¥8,101 million. Cash flow from operating activities was ¥1,394 million, investing activities used ¥218 million, and financing activities used ¥343 million.
  19. FY2021-Q1First-quarter-end cash balance updatedAnnual report

    「Cash and deposits 7,268 7,177」

    Cash and deposits decreased from ¥7,268 million at the end of the previous fiscal year to ¥7,177 million at the end of the first quarter, a decrease of ¥91 million. No cash flow statement was prepared for the cumulative first-quarter period.
  20. FY2020Updated full-year cash balance and cash flowAnnual report

    「At the end of the fiscal year, cash and cash equivalents increased by ¥2,442 million from the end of the previous fiscal year to ¥7,268 million.」

    At the end of the fiscal year, cash and cash equivalents were ¥7,268 million, up ¥2,442 million from the end of the previous fiscal year. Cash flow from operating activities was ¥5,726 million, investing activities used ¥1,485 million, and financing activities used ¥1,799 million.
  21. FY2020-Q3Third-quarter-end cash balance updatedAnnual report

    「Cash and deposits 5,726 8,848」

    Cash and deposits increased from ¥5,726 million at the end of the previous fiscal year to ¥8,848 million at the end of the third quarter, an increase of ¥3,122 million. No cash flow statement was prepared for the cumulative third-quarter period.
  22. FY2020-Q2Updated second-quarter cash balance and cash flowAnnual report

    「At the end of the cumulative second-quarter period, cash and cash equivalents increased by ¥2,652 million from the end of the previous fiscal year to ¥7,478 million.」

    Cash and cash equivalents increased by ¥2,652 million from the end of the previous fiscal year to ¥7,478 million. Cash flow from operating activities was ¥3,483 million, investing activities used ¥1,263 million, and financing activities provided ¥432 million.
  23. FY2020-Q1First-quarter-end cash balance updatedAnnual report

    「Cash and deposits 5,726 6,169」

    Cash and deposits increased from ¥5,726 million at the end of the previous fiscal year to ¥6,169 million at the end of the first quarter, an increase of ¥443 million. No cash flow statement was prepared for the cumulative first-quarter period.
  24. FY2019Updated full-year cash balance and cash flowAnnual report

    「At the end of the fiscal year, cash and cash equivalents decreased by ¥630 million from the end of the previous fiscal year to ¥4,826 million.」

    At the end of FY2019, cash and cash equivalents were ¥4,826 million, down ¥630 million from the end of the previous fiscal year. Operating activities provided ¥2,051 million, investing activities used ¥2,369 million, and financing activities used ¥313 million.
  25. FY2019-Q3Third-quarter-end cash balance updatedAnnual report

    「Cash and deposits 5,457 7,060」

    Cash and deposits were ¥7,060 million at the end of the third quarter, up from ¥5,457 million at the end of the previous fiscal year. No cash flow statement was prepared for the cumulative third-quarter period.
  26. FY2019-Q2Updated second-quarter cash balance and cash flowAnnual report

    「At the end of the cumulative second-quarter period, cash and cash equivalents increased by ¥2,952 million from the end of the previous fiscal year to ¥8,409 million.」

    Cash and cash equivalents increased by ¥2,952 million from the end of the previous fiscal year to ¥8,409 million. Cash flow from operating activities was ¥2,280 million, investing activities used ¥1,020 million, and financing activities provided ¥1,692 million.
  27. FY2019-Q1First-quarter-end cash balance updatedAnnual report

    「Cash and deposits 5,457 6,883」

    Cash and deposits on the quarterly balance sheet increased from ¥5,457 million at the end of the previous fiscal year to ¥6,883 million at the end of the first quarter. No quarterly cash flow statement was prepared for the cumulative first-quarter period.
  28. FY2018Updated full-year cash balance and cash flowAnnual report

    「At the end of the fiscal year, cash and cash equivalents increased by ¥506 million from the end of the previous fiscal year to ¥5,457 million.」

    Cash and cash equivalents increased by ¥506 million from the end of the previous fiscal year. Cash flow from operating activities was ¥1,420 million, investing activities used ¥984 million, and financing activities provided ¥69 million.
  29. FY2018-Q2First statedAnnual report

    「At the end of the cumulative second-quarter period, cash and cash equivalents increased by ¥1,627 million from the end of the previous fiscal year to ¥6,579 million.」

    Cash and cash equivalents increased by ¥1,627 million from the end of the previous fiscal year. Cash flow from operating activities was ¥815 million, investing activities used ¥1,160 million, and financing activities provided ¥1,973 million. Long-term borrowings increased from ¥8,250 million to ¥10,367 million.
Moved together

None of this company's other threads moved the same way in the same document twice or more.

When this could move next
No upcoming earnings preview for Fuso Pharmaceutical Industries yet.
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.
Increase in Cash and Cash Equivalents and Financing Cash Flow from Borrowings | Fuso Pharmaceutical Industries,Ltd. (4538) | Komori